Viracta’s lead program is in clinical development for Epstein Barr Virus-associated cancers.

We will also apply our platform to benefit patients with a range of virus-associated cancers and other serious diseases.

Our viral activation therapy products will be orally administered combination therapy that can be used on an out-patient basis, which will facilitate patient compliance, better outcomes for patients, and contribute to lower overall cost of care.

Viracta’s lead program is in clinical development for Epstein Barr Virus-associated cancers.

We will also apply our platform to benefit patients with a range of virus-associated cancers and other serious diseases.

Our viral activation therapy products will be orally administered combination therapy that can be used on an out-patient basis, which will facilitate patient compliance, better outcomes for patients, and contribute to lower overall cost of care.